A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash - Contacts and Locations

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

This study has been terminated.

Study NCT00343187. Last updated on September 8, 2008. Information provided by Allergan

Please refer to this study by its ClinicalTrials.gov identifier: NCT00343187

Locations


United States, Illinois
	Northwestern University Robert H. Lurie Comprehensive Cancer Center
	Chicago, Illinois, United States, 60611-2941

United States, Pennsylvania
	Fox Chase Cancer Center
	Philadelphia, Pennsylvania, United States, 19111
	Penn State Milton S. Hershey Medical Center
	Hershey, Pennsylvania, United States, 17033

Sponsors and Collaborators

Allergan

Investigators


Study Director:	Steven Garrett, MS, DDS	QLT USA, Inc